Trial Profile
A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Lunacalcipol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors OPKO Health
- 08 Feb 2017 New trial record